The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
47
Urology Centers of Alabama, PC
Change From Baseline for Worst Bladder Pain/Discomfort Scores Overnight / Over-the-day
Each evening and morning the subject responded to the question "Please indicate the worst bladder pain/discomfort you have had overnight/over-the-day" using an 11-point numerical rating scale (NRS) that ranges from 0 = "no bladder pain/discomfort" to 10 = "as bad as you can imagine bladder pain/discomfort."
Time frame: Assessed at Baseline, Weeks 2 and 8. Change from Baseline to Week 2 (Period 1) and Week 8 (Period 2) reported.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Homewood, Alabama, United States
Urological Associates of Southern Arizona
Tucson, Arizona, United States
Applied Research Center of Arkansas
Little Rock, Arkansas, United States
Investigational Site
Escondido, California, United States
Urology Group of Southern California
Los Angeles, California, United States
Hope Clinical Research, LLC
Los Angeles, California, United States
Tri Valley Urology Medical Group
Murrieta, California, United States
Accel Research Sites
DeLand, Florida, United States
Accel Research Site - Neurostudies
Decatur, Georgia, United States
Providea Health Partners LLC
Evergreen Park, Illinois, United States
...and 14 more locations